C
Krystal Biotech, Inc.
KRYS
$188.61
-$0.57-0.30%
C
Hold
2/20/2025Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to C from C- on 2/20/2025 due to a major increase in the valuation index, growth index and efficiency index. Earnings per share increased from $0.91 to $1.5262, net income increased 67.33% from $27.18M to $45.48M, and EBIT increased 18.45% from $34.93M to $41.38M.
Krystal Biotech, Inc. (KRYS) was upgraded to C from C- on 2/20/2025 due to a major increase in the valuation index, growth index and efficiency index. Earnings per share increased from $0.91 to $1.5262, net income increased 67.33% from $27.18M to $45.48M, and EBIT increased 18.45% from $34.93M to $41.38M.
C
Hold
11/5/2024Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to C- from C on 11/5/2024 due to a large decline in the total return index, valuation index and efficiency index.
Krystal Biotech, Inc. (KRYS) was downgraded to C- from C on 11/5/2024 due to a large decline in the total return index, valuation index and efficiency index.
C
Hold
9/19/2024Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to C from C- on 9/19/2024 due to a noticeable increase in the total return index, volatility index and valuation index.
Krystal Biotech, Inc. (KRYS) was upgraded to C from C- on 9/19/2024 due to a noticeable increase in the total return index, volatility index and valuation index.
C
Hold
9/4/2024Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to C- from C on 9/4/2024 due to a large decline in the total return index and growth index. Operating cash flow declined 126.23% from $15.89M to -$4.17M.
Krystal Biotech, Inc. (KRYS) was downgraded to C- from C on 9/4/2024 due to a large decline in the total return index and growth index. Operating cash flow declined 126.23% from $15.89M to -$4.17M.
C
Hold
5/7/2024Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to C from D+ on 5/7/2024 due to a large increase in the total return index, growth index and efficiency index. Operating cash flow increased 319.69% from -$7.23M to $15.89M, EBIT increased 85.34% from $3.14M to $5.82M, and total revenue increased 7.37% from $42.14M to $45.25M.
Krystal Biotech, Inc. (KRYS) was upgraded to C from D+ on 5/7/2024 due to a large increase in the total return index, growth index and efficiency index. Operating cash flow increased 319.69% from -$7.23M to $15.89M, EBIT increased 85.34% from $3.14M to $5.82M, and total revenue increased 7.37% from $42.14M to $45.25M.
D
Sell
5/2/2024Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D+ from C- on 5/2/2024 due to a large decline in the total return index and efficiency index.
Krystal Biotech, Inc. (KRYS) was downgraded to D+ from C- on 5/2/2024 due to a large decline in the total return index and efficiency index.
C
Hold
4/17/2024Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to C- from D+ on 4/17/2024 due to a large increase in the total return index.
Krystal Biotech, Inc. (KRYS) was upgraded to C- from D+ on 4/17/2024 due to a large increase in the total return index.
D
Sell
4/2/2024Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D+ from C- on 4/2/2024 due to a large decline in the total return index.
Krystal Biotech, Inc. (KRYS) was downgraded to D+ from C- on 4/2/2024 due to a large decline in the total return index.
C
Hold
3/14/2024Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to C- from D+ on 3/14/2024 due to a large increase in the total return index and volatility index.
Krystal Biotech, Inc. (KRYS) was upgraded to C- from D+ on 3/14/2024 due to a large increase in the total return index and volatility index.
D
Sell
2/27/2024Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D- on 2/27/2024 due to a major increase in the efficiency index, growth index and solvency index. Total revenue increased 392.55% from $8.56M to $42.14M, EBIT increased 112.07% from -$25.99M to $3.14M, and operating cash flow increased 65.93% from -$21.23M to -$7.23M.
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D- on 2/27/2024 due to a major increase in the efficiency index, growth index and solvency index. Total revenue increased 392.55% from $8.56M to $42.14M, EBIT increased 112.07% from -$25.99M to $3.14M, and operating cash flow increased 65.93% from -$21.23M to -$7.23M.
D
Sell
3/14/2023Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/28/2023Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 2/28/2023 due to a noticeable decline in the total return index and solvency index. The quick ratio declined from 14.07 to 13.14.
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 2/28/2023 due to a noticeable decline in the total return index and solvency index. The quick ratio declined from 14.07 to 13.14.
D
Sell
2/9/2023Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D- on 2/9/2023 due to an increase in the valuation index.
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D- on 2/9/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D+ on 2/8/2023 due to a decline in the growth index, solvency index and valuation index. EBIT declined 9.38% from -$28.75M to -$31.45M, and earnings per share declined from -$1.1003 to -$1.1651.
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D+ on 2/8/2023 due to a decline in the growth index, solvency index and valuation index. EBIT declined 9.38% from -$28.75M to -$31.45M, and earnings per share declined from -$1.1003 to -$1.1651.
D
Sell
8/9/2022Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 8/9/2022 due to a large increase in the total return index, solvency index and growth index. The quick ratio increased from 7.19 to 12.36, and earnings per share increased from -$1.9895 to -$1.1003.
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 8/9/2022 due to a large increase in the total return index, solvency index and growth index. The quick ratio increased from 7.19 to 12.36, and earnings per share increased from -$1.9895 to -$1.1003.
D
Sell
5/31/2022Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
Krystal Biotech, Inc. (KRYS) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
D
Sell
5/13/2022Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and total return index. The quick ratio declined from 17.02 to 7.19.
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and total return index. The quick ratio declined from 17.02 to 7.19.
D
Sell
5/5/2022Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and valuation index.
Krystal Biotech, Inc. (KRYS) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and valuation index.
D
Sell
4/20/2022Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and valuation index.
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and valuation index.
D
Sell
3/2/2022Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 3/2/2022 due to a substantial decline in the total return index and growth index. Operating cash flow declined 188.08% from -$7.26M to -$20.9M, EBIT declined 53.18% from -$15.65M to -$23.98M, and earnings per share declined from -$0.7018 to -$0.9437.
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 3/2/2022 due to a substantial decline in the total return index and growth index. Operating cash flow declined 188.08% from -$7.26M to -$20.9M, EBIT declined 53.18% from -$15.65M to -$23.98M, and earnings per share declined from -$0.7018 to -$0.9437.
D
Sell
2/17/2022Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 2/17/2022 due to a large increase in the total return index and volatility index.
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 2/17/2022 due to a large increase in the total return index and volatility index.
D
Sell
1/27/2022Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 1/27/2022 due to a decline in the total return index.
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 1/27/2022 due to a decline in the total return index.
D
Sell
1/10/2022Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 1/10/2022 due to a large increase in the total return index.
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 1/10/2022 due to a large increase in the total return index.
D
Sell
11/9/2021Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D from D- on 11/9/2021 due to an increase in the growth index, solvency index and valuation index. Operating cash flow increased 28.37% from -$10.13M to -$7.26M, earnings per share increased from -$0.74 to -$0.7018, and EBIT increased 4.52% from -$16.39M to -$15.65M.
Krystal Biotech, Inc. (KRYS) was upgraded to D from D- on 11/9/2021 due to an increase in the growth index, solvency index and valuation index. Operating cash flow increased 28.37% from -$10.13M to -$7.26M, earnings per share increased from -$0.74 to -$0.7018, and EBIT increased 4.52% from -$16.39M to -$15.65M.
D
Sell
11/8/2021Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index, solvency index and growth index. The quick ratio declined from 44.12 to 20.3, EBIT declined 14.21% from -$14.35M to -$16.39M, and operating cash flow declined 4.92% from -$9.65M to -$10.13M.
Krystal Biotech, Inc. (KRYS) was downgraded to D- from D on 11/8/2021 due to a decline in the volatility index, solvency index and growth index. The quick ratio declined from 44.12 to 20.3, EBIT declined 14.21% from -$14.35M to -$16.39M, and operating cash flow declined 4.92% from -$9.65M to -$10.13M.
D
Sell
5/26/2021Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 5/26/2021 due to a major decline in the total return index.
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 5/26/2021 due to a major decline in the total return index.
D
Sell
5/11/2021Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 5/11/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 17.56 to 44.12.
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 5/11/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 17.56 to 44.12.
D
Sell
5/4/2021Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 5/4/2021 due to a decline in the valuation index.
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 5/4/2021 due to a decline in the valuation index.
D
Sell
4/19/2021Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 4/19/2021 due to a significant increase in the total return index.
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 4/19/2021 due to a significant increase in the total return index.
D
Sell
4/6/2020Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 4/6/2020 due to a noticeable decline in the total return index and volatility index.
Krystal Biotech, Inc. (KRYS) was downgraded to D from D+ on 4/6/2020 due to a noticeable decline in the total return index and volatility index.
D
Sell
3/11/2020Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D+ from C- on 3/11/2020 due to a large decline in the total return index, growth index and solvency index. Operating cash flow declined 66.06% from -$4.24M to -$7.05M, earnings per share declined from -$0.2471 to -$0.3089, and EBIT declined 15.2% from -$5.34M to -$6.15M.
Krystal Biotech, Inc. (KRYS) was downgraded to D+ from C- on 3/11/2020 due to a large decline in the total return index, growth index and solvency index. Operating cash flow declined 66.06% from -$4.24M to -$7.05M, earnings per share declined from -$0.2471 to -$0.3089, and EBIT declined 15.2% from -$5.34M to -$6.15M.
C
Hold
12/17/2019Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to C- from D+ on 12/17/2019 due to a major increase in the total return index and efficiency index. Net income increased 20.12% from -$5.35M to -$4.27M, and total capital increased 4.62% from $201.65M to $210.97M.
Krystal Biotech, Inc. (KRYS) was upgraded to C- from D+ on 12/17/2019 due to a major increase in the total return index and efficiency index. Net income increased 20.12% from -$5.35M to -$4.27M, and total capital increased 4.62% from $201.65M to $210.97M.
D
Sell
10/3/2019Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to D+ from C- on 10/3/2019 due to a large decline in the total return index.
Krystal Biotech, Inc. (KRYS) was downgraded to D+ from C- on 10/3/2019 due to a large decline in the total return index.
C
Hold
8/6/2019Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to C- from D+ on 8/6/2019 due to an increase in the total return index, volatility index and growth index.
Krystal Biotech, Inc. (KRYS) was upgraded to C- from D+ on 8/6/2019 due to an increase in the total return index, volatility index and growth index.
D
Sell
4/1/2019Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 4/1/2019 due to a large increase in the total return index, efficiency index and solvency index. Total capital increased 116.53% from $52.29M to $113.23M, and the quick ratio increased from 27.29 to 43.05.
Krystal Biotech, Inc. (KRYS) was upgraded to D+ from D on 4/1/2019 due to a large increase in the total return index, efficiency index and solvency index. Total capital increased 116.53% from $52.29M to $113.23M, and the quick ratio increased from 27.29 to 43.05.
D
Sell
10/1/2018Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D from D- on 10/1/2018 due to a noticeable increase in the total return index, volatility index and growth index. Operating cash flow increased 31.7% from -$2.37M to -$1.62M.
Krystal Biotech, Inc. (KRYS) was upgraded to D from D- on 10/1/2018 due to a noticeable increase in the total return index, volatility index and growth index. Operating cash flow increased 31.7% from -$2.37M to -$1.62M.
D
Sell
6/5/2018Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to D- from E+ on 6/5/2018 due to a large increase in the volatility index and total return index.
Krystal Biotech, Inc. (KRYS) was upgraded to D- from E+ on 6/5/2018 due to a large increase in the volatility index and total return index.
E
Sell
3/1/2018Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to E+ from E- on 3/1/2018 due to an increase in the volatility index.
Krystal Biotech, Inc. (KRYS) was upgraded to E+ from E- on 3/1/2018 due to an increase in the volatility index.
E
Sell
2/16/2018Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to E- from E on 2/16/2018 due to a large decline in the volatility index.
Krystal Biotech, Inc. (KRYS) was downgraded to E- from E on 2/16/2018 due to a large decline in the volatility index.
E
Sell
1/3/2018Upgraded
Krystal Biotech, Inc. (KRYS) was upgraded to E from E- on 1/3/2018 due to a major increase in the volatility index, total return index and valuation index.
Krystal Biotech, Inc. (KRYS) was upgraded to E from E- on 1/3/2018 due to a major increase in the volatility index, total return index and valuation index.
E
Sell
12/19/2017Downgrade
Krystal Biotech, Inc. (KRYS) was downgraded to E- from E on 12/19/2017 due to a significant decline in the volatility index.
Krystal Biotech, Inc. (KRYS) was downgraded to E- from E on 12/19/2017 due to a significant decline in the volatility index.
E
Sell
12/13/2017None
Krystal Biotech, Inc. (KRYS) was downgraded to E from U on 12/13/2017.
Krystal Biotech, Inc. (KRYS) was downgraded to E from U on 12/13/2017.
NASDAQ
03/20/2025 4:00PM Eastern
Quotes delayed
